United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Two years in, is Lundbeck’s bexicaserin redefining how we treat drug-resistant seizures? Lundbeck’s bexicaserin shows two-year seizure control in rare epilepsies. Explore how the durable data could redefine drug development in childhood DEEs. byVenkateshDecember 7, 2025